about
The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptorRole of ketamine in acute postoperative pain management: a narrative reviewPositron emission tomography molecular imaging of dopaminergic system in drug addictionPossible pathophysiology of ketamine-related cystitis and associated treatment strategiesR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effectsChronic ketamine administration modulates midbrain dopamine system in miceDecreased Thalamocortical Connectivity in Chronic Ketamine UsersEphenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist propertiesA Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.NMDAR inhibition-independent antidepressant actions of ketamine metabolites.The prevalence and natural history of urinary symptoms among recreational ketamine users.Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantineOral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case SeriesRepeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.Ketamine alters cortical integration of GABAergic interneurons and induces long-term sex-dependent impairments in transgenic Gad67-GFP miceRapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples.Ketamine for chronic pain: risks and benefits.The validity and reliability of the Mandarin Chinese version of the drug abuse screening test among adolescents in TaiwanGlutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users.Ketamine use among regular tobacco and alcohol users as revealed by respondent driven sampling in Taipei: prevalence, expectancy, and users' risky decision makingPrevalence of new psychoactive substances: A retrospective study in hair.Gender differences in subjective discontinuation symptoms associated with ketamine use.The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsKetamine and phencyclidine: the good, the bad and the unexpected.Clinical applications of hallucinogens: A review.Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation.Effects of midazolam, pentobarbital and ketamine on the mRNA expression of ion channels in a model organism Daphnia pulex.A family-oriented treatment program for youths with ketamine abuse and their caregivers: a pilot study in Taiwan.Effects of ketamine exposure on dopamine concentrations and dopamine type 2 receptor mRNA expression in rat brain tissue.Diabetes alters the blood glucose response to ketamine in streptozotocin-diabetic ratsExperience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case reportNeurocognitive Changes after Sustained Ketamine Administration in Children with Chronic Pain.Age-Dependent Degeneration of Mature Dentate Gyrus Granule Cells Following NMDA Receptor Ablation.Ketamine-Based Anesthetic Protocols and Evoked Potential Monitoring: A Risk/Benefit Overview.Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers.
P2860
Q21089799-C670C8C0-866B-47A8-B4F2-55A97327065DQ26779981-3A93B76A-97AE-4850-A931-414ABD7D5DF2Q26992051-510E8398-269F-4EE3-82B5-DC04E0AD94F6Q27013111-E28B93BB-4BB0-44CE-954F-F8077FA54757Q28266846-C8D39077-D2E3-4483-85B9-726126CDC3C4Q28482530-B0A92C27-11B1-4C23-934E-590688A6C852Q28555039-B48E26C9-F484-4122-8753-8B36615077BAQ28820763-360CD030-B93E-4CCC-9991-D4175684D3E3Q30361531-EC84745A-34C2-426E-BAC8-617DB8F62F0BQ30370600-D9148D7C-8050-431B-9441-1495ED47A957Q30414279-62367C8B-427F-47EE-AB09-7915A277FB09Q30458884-0428E692-23E8-4250-B5A0-BCD289319D43Q30491706-7BCA719E-6036-4BE5-8EB5-B563D3DAD8DEQ30547324-D0D5E7CE-89C4-4DF5-BCD9-14D211172463Q30585962-AD62B4B7-0940-4C82-83A8-86DD6585DF3BQ30695515-48BE1638-F912-4A2C-8361-0A2EF0C75FCFQ30995949-04B83A07-54A0-468E-86CB-FF7BCB1E0879Q33582045-90F68955-E6E0-4057-856E-8D4A5650F41BQ33771651-85CCDEB0-038E-4ABF-B564-875C86A2E614Q33874459-8247D8A3-B275-47C8-BF01-EB77DCB120BAQ33937677-75FE93E2-E39D-45F8-B237-24B2A4354815Q34247768-161560E5-E7F3-45A4-A9F3-E8881EE2FD17Q34270004-090662EF-A78C-4D71-AEBD-FE7F9B8AFD5FQ34283302-A6A39B76-8339-4F7A-9EDF-AAA32B42A796Q34406732-2CFB0574-27DF-458F-93F7-1ADA6C0F9553Q34444632-741817C0-A34C-4DC7-B3F0-E19FEE3329D8Q34480719-5E4B1607-14E5-4E82-B565-DC5981E19896Q34535259-398153C3-A513-4467-96C5-564C325E2857Q34630511-E640DF33-BC25-4930-AC42-E50C4E7AECE3Q35019677-4515FB46-DF53-4343-934C-A1D0C429EFBAQ35924382-AD616E57-56AF-4B38-9DB0-DAF41CFE8B7DQ36046542-9327DFDF-2659-4CCA-AACB-3AF3CE1D4E1CQ36046647-751ACE44-8DC6-4A6C-A0B4-4660463E0121Q36189138-D502AB61-1D72-4358-A0F6-F6A8020C05AFQ36200926-1DA8D6FC-1789-41C6-86BF-118AABE5FEC1Q36453029-77A96121-561D-4E2F-B247-A262567340C4Q36582543-D6C3E90A-C528-479E-9DF6-68575D7C849EQ36733346-2C5D7BA8-32EB-4A9F-A66E-68CECEF91759Q36899381-CBCB070F-D74C-49C6-A075-5EB03551D6FFQ36956267-8EE12C73-143D-4FFE-936A-3624AEBB470F
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ketamine use: a review.
@ast
Ketamine use: a review.
@en
Ketamine use: a review.
@nl
type
label
Ketamine use: a review.
@ast
Ketamine use: a review.
@en
Ketamine use: a review.
@nl
prefLabel
Ketamine use: a review.
@ast
Ketamine use: a review.
@en
Ketamine use: a review.
@nl
P2093
P2860
P1433
P1476
Ketamine use: a review.
@en
P2093
Celia J A Morgan
H Valerie Curran
Independent Scientific Committee on Drugs
P2860
P356
10.1111/J.1360-0443.2011.03576.X
P407
P577
2011-07-22T00:00:00Z